Although our SEC6 predictor needs to be further validated in larger cohorts of chemotherapy‐receiving patients and prospective analyses, SEC6 recapitulates the prognostic information to identify high‐risk CRC subtypes and facilitate the development of novel clinical tools for a correct patient stratification. The gene discussed is EXOC3; the disease is colorectal carcinoma.